n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Ariad Pharma: The Contrarian Long Thesis

Ariad Pharma: The Contrarian Long Thesis

Iclusig may find use in other cancers and '113 is better than the market believes.

ARIAD To Host Conference Call And Webcast Discussion Of Third Quarter 2013 Financial Results On November 6, 2013

ARIAD To Host Conference Call And Webcast Discussion Of Third Quarter 2013 Financial Results On November 6, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2013 financial results on Wednesday, November 6, 2013, before the market opens.

Ariad Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

Ariad Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2013 -- ARIA

ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2013 -- ARIA

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased ARIAD Pharmaceuticals, Inc.

Girard Gibbs LLP Announces Investigation Of ARIAD (ARIA) Pharmaceuticals, Inc.

Girard Gibbs LLP Announces Investigation Of ARIAD (ARIA) Pharmaceuticals, Inc.

Girard Gibbs LLP is investigating potential claims on behalf of investors who purchased ARIAD Pharmaceuticals, Inc.

Trade-Ideas: Ariad Pharmaceuticals (ARIA) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Ariad Pharmaceuticals (ARIA) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

Ariad Forced to Shutter Vital Study of Iclusig Due to Toxicity

Ariad Forced to Shutter Vital Study of Iclusig Due to Toxicity

With the EPIC study shuttered, Ariad's hopes of boosting Iclusig sales are dashed.

ARIAD Announces Discontinuation Of The Phase 3 Epic Trial Of Iclusig In Patients With Newly Diagnosed Chronic Myeloid Leukemia

ARIAD Announces Discontinuation Of The Phase 3 Epic Trial Of Iclusig In Patients With Newly Diagnosed Chronic Myeloid Leukemia

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it is discontinuing the Phase 3 EPIC ( Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig ® (ponatinib)...

Trade-Ideas: Ariad Pharmaceuticals (ARIA) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Ariad Pharmaceuticals (ARIA) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

ALERT: The Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit On Behalf Of Ariad Pharmaceuticals Inc. Investors - ARIA

ALERT: The Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit On Behalf Of Ariad Pharmaceuticals Inc. Investors - ARIA

The Rosen Law Firm today announced that a class action lawsuit has been filed on behalf of all purchasers of the securities of Ariad Pharmaceuticals Inc.

Jim Cramer's Top Stock Picks: ARIA ACHN BA GPOR ASNA COG

Jim Cramer's Top Stock Picks: ARIA ACHN BA GPOR ASNA COG

Ascena is the right retailer for the current environment while Boeing remains the best-in-class plane maker.

Jim Cramer's 'Mad Money' Recap: A Glimmer of Hope

Jim Cramer's 'Mad Money' Recap: A Glimmer of Hope

They're negotiating in Washington, and that gave the markets something to cheer about, Cramer says. But that may not last.

SHAREHOLDER ALERT: Brower Piven Announces An Investigation Of ARIAD Pharmaceuticals, Inc. For Potential Violations Of The Federal Securities Laws

SHAREHOLDER ALERT: Brower Piven Announces An Investigation Of ARIAD Pharmaceuticals, Inc. For Potential Violations Of The Federal Securities Laws

Brower Piven, A Professional Corporation, has commenced an investigation of potential securities law violations by ARIAD Pharmaceuticals, Inc.

U.S. Stocks Get Caught Between Yellen and the Shutdown

U.S. Stocks Get Caught Between Yellen and the Shutdown

Investors juggle conflicting forces of a looming default against more stimulus with Yellen as the next Fed chief.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Claims On Behalf Of Shareholders Of ARIAD Pharmaceuticals, Inc.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Claims On Behalf Of Shareholders Of ARIAD Pharmaceuticals, Inc.

Levi & Korsinsky is investigating potential claims on behalf of purchasers of ARIAD Pharmaceuticals, Inc.

I Was Wrong About Ariad Pharma and Here's Why

I Was Wrong About Ariad Pharma and Here's Why

David Sobek explains what went wrong with the bull thesis on Ariad Pharma and its leukemia drug Iclusig.

ARIA SHAREHOLDER ALERT: The Law Firm Of Wohl & Fruchter LLP Announces Investigation Of Ariad Pharmaceuticals Inc.

ARIA SHAREHOLDER ALERT: The Law Firm Of Wohl & Fruchter LLP Announces Investigation Of Ariad Pharmaceuticals Inc.

The law firm of Wohl & Fruchter LLP is investigating possible violations of federal securities laws by officers and directors of Ariad Pharmaceuticals Inc.

Ariad Pharma Plunges On Disclosure Of Iclusig Toxicity

Ariad Pharma Plunges On Disclosure Of Iclusig Toxicity

Ariad is forced to admit that Iclusig causes far more blood clots and heart-related side effects.

Trade-Ideas: Ariad Pharmaceuticals (ARIA) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Ariad Pharmaceuticals (ARIA) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Ariad Pharmaceuticals (ARIA) as a pre-market mover with heavy volume candidate

ARIAD Announces Changes In The Clinical Development Program Of Iclusig

ARIAD Announces Changes In The Clinical Development Program Of Iclusig

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig ® (ponatinib) and actions that it is taking following...

ARIAD Presents Updated Phase 1/2 Data On AP26113 In Patients With Non-Small Cell Lung Cancer

ARIAD Presents Updated Phase 1/2 Data On AP26113 In Patients With Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from...

Beware of 'Earnings Torpedos'

Some of the market's favorite stocks have entered a danger zone.

4 Drugs Stocks Dragging The Industry Down

4 Drugs Stocks Dragging The Industry Down

TheStreet highlights 4 stocks pushing the drugs industry lower today.

Biotech Stock Mailbag: Agenus, Aegerion, Ariad

Biotech Stock Mailbag: Agenus, Aegerion, Ariad

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Ariad Pharma: Dismantling The Short Thesis

Ariad Pharma: Dismantling The Short Thesis

Iclusig is not any more toxic than its competing leukemia drugs and the sales potential remains strong.

Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13

Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

ARIAD Announces Updated Data On AP26113 To Be Presented At The European Cancer Congress 2013 Meeting

ARIAD Announces Updated Data On AP26113 To Be Presented At The European Cancer Congress 2013 Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated data from its Phase 1/2 trial of AP26113, an investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor...

Insider Trading Alert - Fiserv And 4 Others Traded By Insiders

Insider Trading Alert - Fiserv And 4 Others Traded By Insiders

Stocks with insider trader activity include FISV, MSFT, UGI, PETM and ARIA

ARIAD To Present At Upcoming Investor Conferences

ARIAD To Present At Upcoming Investor Conferences

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will provide an overview of the Company’s business at two upcoming investor conferences being held next week: The...